Skip to content

Sublingual misoprostol and oxytocin versus oxytocin alone for preventing primary postpartum hemorrhage after vaginal delivery in Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria: A double-blind randomised placebo controlled study

Sublingual misoprostol and oxytocin versus oxytocin alone for preventing primary postpartum hemorrhage after vaginal delivery in Nnamdi Azikiwe University Teaching Hospital Nnewi, Nigeria: A double-blind randomised placebo controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202506646284255
Enrollment
198
Registered
2025-06-19
Start date
2025-07-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Misoprostol and oxytocin
Oxytocin 10 i.u

Sponsors

Ogonna Ezenwafor
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: These will include all parturients who are 18 years or older Gestational ages from 37 to 41 weeks In active labour and having successful vaginal deliveries Consent to be part of the study.

Exclusion criteria

Exclusion criteria: These will include parturients who do not give their consent, preterm delivery, caesarean section, patients with anaemia (Hb < 10g/dl), coagulation disorders, antepartum haemorrhage, previous history of uterine rupture, conditions requiring prophylactic oxytocin infusion after delivery (e.g. multiple pregnancy, previous history of PPH, etc) Any contraindications to prostaglandin use. Patients who presented in third stage of labour Patient with perineal lacerations and cervical laceration

Design outcomes

Primary

MeasureTime frame
Mean postpartum blood loss between the groups

Secondary

MeasureTime frame
II. Secondary outcome measures will include; the need for additional uterotonics, blood transfusion, and adverse effects of medication (nausea, vomiting, shivering, hypotension etc).

Countries

Nigeria

Contacts

Public ContactEzeama Chukwuemeka

Professor of OBGYN

co.ezeama@unizik.edu.ng+2348037167284

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026